{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:27:33Z","timestamp":1777566453755,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81200371"],"award-info":[{"award-number":["81200371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1432250"],"award-info":[{"award-number":["U1432250"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471773"],"award-info":[{"award-number":["81471773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473088"],"award-info":[{"award-number":["81473088"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1532154"],"award-info":[{"award-number":["U1532154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703559"],"award-info":[{"award-number":["81703559"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21708044"],"award-info":[{"award-number":["21708044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"crossref","award":["2016YFA0400900"],"award-info":[{"award-number":["2016YFA0400900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Science and Technology Program of Anhui Province","award":["16030801114"],"award-info":[{"award-number":["16030801114"]}]},{"name":"Major Science and Technology Program of Anhui Province","award":["17030801025"],"award-info":[{"award-number":["17030801025"]}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1708085MH208"],"award-info":[{"award-number":["1708085MH208"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1808085MH274"],"award-info":[{"award-number":["1808085MH274"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1208085QH154"],"award-info":[{"award-number":["1208085QH154"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1708085MH224"],"award-info":[{"award-number":["1708085MH224"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of the Anhui Higher Education Institutions of China","award":["KJ2018ZD020"],"award-info":[{"award-number":["KJ2018ZD020"]}]},{"DOI":"10.13039\/501100002367","name":"CAS","doi-asserted-by":"publisher","award":["QYZDB-SSW-SLH037"],"award-info":[{"award-number":["QYZDB-SSW-SLH037"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejmech.2018.10.007","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T06:23:01Z","timestamp":1538720581000},"page":"61-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia"],"prefix":"10.1016","volume":"160","author":[{"given":"Xuesong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beilei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongru","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenquan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingwang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-2547","authenticated-orcid":false,"given":"Qingsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9513-3591","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.10.007_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of Abl family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2018.10.007_bib2","first-page":"55","article-title":"Chronic myeloid leukemia: Attributes of break point cluster region-Abelson (Bcr-Abl)","volume":"3","author":"Rana","year":"2011","journal-title":"J.\u00a0Cancer Res. Clin."},{"key":"10.1016\/j.ejmech.2018.10.007_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-642-29467-9_6","article-title":"Molecular biology of chronic myeloid leukemia","author":"Sacha","year":"2012","journal-title":"Molecular Aspects of Hematologic Malignancies"},{"key":"10.1016\/j.ejmech.2018.10.007_bib4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Swayers","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.10.007_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: insights from Bcr-Abl","volume":"21","author":"Eck","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.10.007_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.10.007_bib7","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2018.10.007_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The Bcr-Abl story: bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2018.10.007_bib9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.10.007_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2018.10.007_bib11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd1579","article-title":"Strategies to overcome resistance to targeted protein kinase inhibitors","volume":"3","author":"Daub","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.10.007_bib12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2018.10.007_bib13","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","article-title":"Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity","volume":"44","author":"Boschelli","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.007_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel Abl kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.10.007_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2018.10.007_bib16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2018.10.007_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"Fda-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2018.10.007_bib18","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.007_bib19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of Gzd824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.007_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the Bcr-Abl1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor Dcc-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2018.10.007_bib21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.10.007_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor Abl001 enables dual targeting of Bcr-Abl1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.10.007_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1747-0285.2007.00556.x","article-title":"Crystal structure of the T315I mutant of Abl kinase","volume":"70","author":"Zhou","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2018.10.007_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits Bcr-Abl1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.10.007_bib25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejmech.2014.11.029","article-title":"ChemInform Abstract: synthesis of indazole motifs and their medicinal importance: an overview","volume":"90","author":"Gaikwad","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.007_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Neil","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2018.10.007_bib27","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1073\/pnas.0812413106","article-title":"KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2018.10.007_bib28","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1021\/acs.jmedchem.6b00200","article-title":"Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benz amide (CHMFL-KIT-110) as a selective, potent, and orally Available type II c-KIT kinase inhibitor for gastrointestinal stromal tumors (GISTs)","volume":"59","author":"Wang","year":"2016","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418308699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418308699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T06:00:07Z","timestamp":1589954407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418308699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":28,"alternative-id":["S0223523418308699"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.007","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}